Yahoo Finance 
Respiratory Drug Delivery Technologies Market Report 2022-2032
Forecasts by Product (Formulations, Devices), by Type (Dry Powder, Suspension Aerosol, Solution Aerosol), by Product Type (Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIs), Nebulizers, Accessories), by Nebulizers Type (Soft Mist Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers), by Canister Type (Plain Canisters, Coated Canister), by Application (Asthma, COPD, Cystic Fibrosis, Others), by End-user (Homecare, Hospitals & Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios
New York, June 21, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Respiratory Drug Delivery Technologies Market Report 2022-2032" - https://www.reportlinker.com/p06288089/?utm_source=GNW
The Respiratory Drug Delivery Technologies Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The Rise in Prevalence of Respiratory Diseases, Technological Advancements, And Outbreak of COVID-19 Pandemic Are Driving the Market Growth
Some of the major forces propelling the global respiratory drug delivery technologies market include an increase in prevalence and incidence of respiratory diseases, technological advancements in respiratory drug delivery, and the outbreak of the Covid-19 pandemic. Furthermore, the use of nanoparticles and polymeric carriers in respiratory drug delivery systems is expected to propel the overall market. Some trends in the field are indicated by recent advances in inhaled devices and formulations. High-dose dry powder alternatives are becoming increasingly popular with nebulized formulations and would be supported by the development of new high-dose (> 100 mg) DPI (Dry Powder Inhalers) variants. Single-use disposable dry powder inhalers can be helpful in the treatment of various respiratory diseases including infectious diseases.
Nebulizers, particularly software-aided systems using smart cards and an electronic control unit that can accurately direct lung deposition and total dosage, will play a crucial role in novel cancer therapies and improve the reliability of inhaled therapy clinical trials. A greater proportion of future formulations of aerosols is also expected to involve repurposed drugs.
The use of nanoparticles in pulmonary drug delivery formulations for DPI (Dry Powder Inhalers) remains a hot topic. Nanoparticles of the same drug were found to have significantly less impact on the oropharyngeal region and higher peripheral deposition in humans compared to micronized salbutamol sulfate, suggesting greater local bioavailability for a sustained period of time due to their smaller size.
Barriers of Respiratory Drugs Delivery
The respiratory system has evolved self-defence methods to keep inhaled medication particles out of the lungs and to eliminate or inactivate them once established and hence pulmonary drug administration is relatively difficult. In addition to mechanical, pharmacological, and immunological barriers, behavioural barriers such as compliance and inhaler technique have a negative impact on pulmonary medication delivery. Strategies for mitigating the effects of these barriers include the use of inhaler devices and compositions that efficiently deliver medicine to the lungs, adequate inhaler technique, and increased patient education. If respiratory drug delivery devices are used appropriately, the pulmonary route offers enormous opportunities, often meeting unmet clinical requirements.
What Questions Should You Ask before Buying a Market Research Report?
• How is the respiratory drug delivery technologies market evolving?
• What is driving and restraining the respiratory drug delivery technologies market?
• How will each respiratory drug delivery technologies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each respiratory drug delivery technologies submarket develop from 2022 to 2032?
• What will be the main drivers for the overall market from 2022 to 2032?
• Will leading respiratory drug delivery technologies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the respiratory drug delivery technologies projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of respiratory drug delivery technologies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the respiratory drug delivery technologies market?
• Where is the respiratory drug delivery technologies market heading? And how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and? C-suite?
You need to discover how this will impact the respiratory drug delivery technologies market today, and over the next 10 years:
• Our 587-page report provides 456 tables and 454 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the respiratory drug delivery technologies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory drug delivery technologies prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
By Product
• Formulations
• Devices
By Type
• Dry Powder
• Suspension Aerosol
• Solution Aerosol
By Product Type
• Metered Dose Inhalers (MDIS)
• Dry Powder Inhalers (DPIS)
• Nebulizers and Accessories
By Nebulizers Type
• Soft Mist Nebulizers
• Jet Nebulizers
• Ultrasonic Nebulizers
By Canister Type
• Plain Canisters
• Coated Canister
By Application
• Asthma
• COPD
• Cystic Fibrosis
• Others
By End User
• Homecare
• Hospitals & Clinics
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 21 leading national markets:
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Respiratory Drug Delivery Technologies Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies
• AptarGroup, Inc.
• AstraZeneca plc.
• Boehringer Ingelheim GmbH
• Cipla Limited
• Graham Field Health Products
• GSK Corporation
• Medisana GmbH.
• Merck & Co., Inc.
• Novartis AG
• Omron Corporation
• Philips Respironics
• Recipharm Ab.
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceuticals
• 3M Healthcare
Overall world revenue for Respiratory Drug Delivery Technologies Market, 2022 to 2032 in terms of value the market will surpass US$59.51 billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Respiratory Drug Delivery Technologies Market, 2022 to 2032 Market report help you?
In summary, our 580+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Respiratory Drug Delivery Technologies Market, 2022 to 2032 Market, with forecasts, type company size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 21 key national markets – See forecasts for the Respiratory Drug Delivery Technologies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Respiratory Drug Delivery Technologies Market, 2022 to 2032.
Read the full report: https://www.reportlinker.com/p06288089/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
